(1) Behr C, Goltzene M, Kosmalski G, Hirsch E, and Ryvlin P. Epidemiology of epilepsy. Revue neurologique. (2016) 172: 27-36.
(2) LaRoche SM and Helmers SL. The new antiepileptic drugs: scientific review. Jama. (2004) 291: 605-14.
(3) Elger CE. Epilepsy in 2015: Classic antiepileptic drugs under fire, and new options emerge. Nat Rev Neurol. (2016) 12: 72-4.
(4) Paoletti P. Molecular basis of NMDA receptor functional diversity. European Journal of Neuroscience. (2011) 33: 1351-65.
(5) Förstermann U and Sessa WC. Nitric oxide synthases: regulation and function. European heart journal. (2011) 33: 829-37.
(6) Navidpour L, Shafaroodi H, Miri R, Dehpour AR, and Shafiee A. Lipophilic 4-imidazoly-1, 4-dihydropyridines: synthesis, calcium channel antagonist activity and protection against pentylenetetrazole-induced seizure. Il Farmaco. (2004) 59: 261-9.
(7) Mohseni G, Ostadhadi S, Akbarian R, Chamanara M, Norouzi-Javidan A, and Dehpour A-R. Anticonvulsant effect of dextrometrophan on pentylenetetrazole-induced seizures in mice: Involvement of nitric oxide and N-methyl-d-aspartate receptors. Epilepsy & Behavior. (2016) 65: 49-55.
(8) Lesani A, Javadi-Paydar M, Khodadad TK, Asghari-Roodsari A, Shirkhodaei M, Norouzi A, and Dehpour AR. Involvement of the nitric oxide pathway in the anticonvulsant effect of tramadol on pentylenetetrazole-induced seizures in mice. Epilepsy Behav. (2010) 19: 290-5.
(9) Corbalán R, Chatauret N, Behrends S, Butterworth RF, and Felipo V. Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients. Hepatology. (2002) 36: 1155-62.
(10) Ding JD, Burette A, Nedvetsky PI, Schmidt HH, and Weinberg RJ. Distribution of soluble guanylyl cyclase in the rat brain. Journal of Comparative Neurology. (2004) 472: 437-48.
(11) Mergia E, Russwurm M, Zoidl G, and Koesling D. Major occurrence of the new α2β1 isoform of NO-sensitive guanylyl cyclase in brain. Cellular signalling. (2003) 15: 189-95.
(12) Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends in neurosciences. (1991) 14: 60-7.
(13) Bahremand A, Nasrabady SE, Ziai P, Rahimian R, Hedayat T, Payandemehr B, and Dehpour AR. Involvement of nitric oxide-cGMP pathway in the anticonvulsant effects of lithium chloride on PTZ-induced seizure in mice. Epilepsy research. (2010) 89: 295-302.
(14) Jennings E, Ryan R, and Christie M. Effects of sumatriptan on rat medullary dorsal horn neurons. Pain. (2004) 111: 30-7.
(15) Stepień A, Chalimoniuk M, and Strosznajder J. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor‐evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices. Cephalalgia. (1999) 19: 859-65.
(16) Tepper SJ, Rapoport AM, and Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Archives of neurology. (2002) 59: 1084-8.
(17) Hassanipour M, Rajai N, Rahimi N, Fatemi I, Jalali M, Akbarian R, Shahabaddini A, Nazari A, Amini-Khoei H, and Dehpour AR. Sumatriptan effects on morphine-induced antinociceptive tolerance and physical dependence: The role of nitric oxide. European journal of pharmacology. (2018) 835: 52-60.
(18) Stepien A and Chalimoniuk M. Level of nitric oxide‐dependent cGMP in patients with migraine. Cephalalgia. (1998) 18: 631-4.
(19) Stean TO, Atkins AR, Heidbreder CA, Quinn LP, Trail BK, and Upton N. Postsynaptic 5-HT1B receptors modulate electroshock-induced generalised seizures in rats. British journal of pharmacology. (2005) 144: 628-35.
(20) Wesolowska A, Nikiforuk A, and Chojnacka-Wojcik E. Anticonvulsant effect of the selective 5-HT1B receptor agonist CP 94253 in mice. Eur J Pharmacol. (2006) 541: 57-63.
(21) Gooshe M, Ghasemi K, Rohani MM, Tafakhori A, Amiri S, Aghamollaii V, Ahmadi M, and Dehpour AR. Biphasic effect of sumatriptan on PTZ-induced seizures in mice: Modulation by 5-HT1B/D receptors and NOS/NO pathway. European journal of pharmacology. (2018) 824: 140-7.
(22) Ghasemi M, Shafaroodi H, Nazarbeiki S, Meskar H, Ghasemi A, Bahremand A, Ziai P, and Dehpour AR. Inhibition of NMDA receptor/NO signaling blocked tolerance to the anticonvulsant effect of morphine on pentylenetetrazole-induced seizures in mice. Epilepsy Res. (2010) 91: 39-48.
(23) Rahimi N, Hassanipour M, Yarmohammadi F, Faghir-Ghanesefat H, Pourshadi N, Bahramnejad E, and Dehpour A. Nitric oxide and glutamate are contributors of anti-seizure activity of rubidium chloride: a comparison with lithium. Neuroscience letters. (2019) 134349.
(24) Heydari A and Davoudi S. The effect of sertraline and 8-OH-DPAT on the PTZ_induced seizure threshold: Role of the nitrergic system. Seizure. (2017) 45: 119-24.
(25) Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. Journal of Chromatography B. (2007) 851: 51-70.
(26) Javadi S, Ejtemaeimehr S, Keyvanfar HR, Moghaddas P, Aminian A, Rajabzadeh A, Mani AR, and Dehpour AR. Pioglitazone potentiates development of morphine-dependence in mice: Possible role of NO/cGMP pathway. Brain research. (2013) 1510: 22-37.
(27) Esmaili Z and Heydari A. Effect of acute caffeine administration on PTZ-induced seizure threshold in mice: Involvement of adenosine receptors and NO-cGMP signaling pathway. Epilepsy research. (2019) 149: 1-8.
(28) Fisher RS, Boas WVE, Blume W, Elger C, Genton P, Lee P, and Engel Jr J. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. (2005) 46: 470-2.
(29) Meng F, You Y, Liu Z, Liu J, Ding H, and Xu R. Neuronal calcium signaling pathways are associated with the development of epilepsy. Molecular medicine reports. (2015) 11: 196-202.
(30) Mies G. Neuroprotective effect of sumatriptan, a 5-HT1D receptor agonist, in focal cerebral ischemia of rat brain. Journal of Stroke and Cerebrovascular Diseases. (1998) 7: 242-9.
(31) Pathak S, Cottingham EM, and McConville BJ. The use of sumatriptan in the treatment of obsessive-compulsive disorder in an adolescent. Journal of child and adolescent psychopharmacology. (2003) 13: 93-4.
(32) Amital D, Fostick L, Sasson Y, Kindler S, Amital H, and Zohar J. Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. (2005) 15: 279-82.
(33) Moezi L, Shafaroodi H, Hassanipour M, Fakhrzad A, Hassanpour S, and Dehpour AR. Chronic administration of atorvastatin induced anti-convulsant effects in mice: the role of nitric oxide. Epilepsy Behav. (2012) 23: 399-404.
(34) Rameau GA, Chiu L-Y, and Ziff EB. NMDA receptor regulation of nNOS phosphorylation and induction of neuron death. Neurobiology of aging. (2003) 24: 1123-33.
(35) Rajasekaran K, Jayakumar R, and Venkatachalam K. Increased neuronal nitric oxide synthase (nNOS) activity triggers picrotoxin-induced seizures in rats and evidence for participation of nNOS mechanism in the action of antiepileptic drugs. Brain research. (2003) 979: 85-97.
(36) Shafaroodi H, Moezi L, Ghorbani H, Zaeri M, Hassanpour S, Hassanipour M, and Dehpour AR. Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide. Brain Res Bull. (2012) 87: 544-50.
(37) Homayoun H, Khavandgar S, Namiranian K, Gaskari SA, and Dehpour AR. The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res. (2002) 48: 33-41.
(38) De Luca G, Di Giorgio RM, Macaione S, Calpona PR, Di Paola ED, Costa N, Cuzzocrea S, Citraro R, Russo E, and De Sarro G. Amino acid levels in some brain areas of inducible nitric oxide synthase knock out mouse (iNOS-/-) before and after pentylenetetrazole kindling. Pharmacol Biochem Behav. (2006) 85: 804-12.
(39) Itoh K and Watanabe M. Paradoxical facilitation of pentylenetetrazole-induced convulsion susceptibility in mice lacking neuronal nitric oxide synthase. Neuroscience. (2009) 159: 735-43.
(40) Jand A and Palizvan MR. Sumatriptan, an Antimigraine Drug, Inhibits Pentylenetetrazol-induced Seizures in NMRI Mice. Drug research. (2017) 67: 179-82.
(41) Akerman S, Williamson DJ, Kaube H, and Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. European journal of pharmacology. (2002) 452: 223-8.
(42) Bellamy TC and Garthwaite J. The receptor-like properties of nitric oxide-activated soluble guanylyl cyclase in intact cells. Mol Cell Biochem. (2002) 230: 165-76.
(43) Meldrum B and Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends in pharmacological sciences. (1990) 11: 379-87.
(44) Bahramnjead E, Roodsari SK, Rahimi N, Etemadi P, Aghaei I, and Dehpour AR. Effects of modafinil on clonic seizure threshold induced by pentylenetetrazole in mice: involvement of glutamate, nitric oxide, GABA, and serotonin pathways. Neurochemical research. (2018) 43: 2025-37.
(45) Gibb BJ and Garthwaite J. Subunits of the nitric oxide receptor, soluble guanylyl cyclase, expressed in rat brain. European Journal of Neuroscience. (2001) 13: 539-44.
(46) Smith SL and Otis TS. Persistent changes in spontaneous firing of Purkinje neurons triggered by the nitric oxide signaling cascade. J Neurosci. (2003) 23: 367-72.
(47) Bidmon H-J, Starbatty J, Görg B, Zilles K, and Behrends S. Cerebral expression of the α2-subunit of soluble guanylyl cyclase is linked to cerebral maturation and sensory pathway refinement during postnatal development. Neurochemistry international. (2004) 45: 821-32.
(48) Solmaz V, Aksoy D, Yurtogulları S, Semiz M, Aydemir E, and Erbas O. The Effects of Methylene Blue and Tadalafil in Pentylenetetrazole Induced Convulsion Model. GULHANE MEDICAL JOURNAL. (2016) 58:
(49) Itoh K, Watanabe M, Yoshikawa K, Kanaho Y, Berliner L, and Fujii H. Magnetic resonance and biochemical studies during pentylenetetrazole-kindling development: the relationship between nitric oxide, neuronal nitric oxide synthase and seizures. Neuroscience. (2004) 129: 757-66.